\
Description
The
goal of this report is to characterize, portray, and estimate the market on the
premise of sort, application, therapeutic condition, and area. It gives
point-by-point data with respect to the main considerations influencing the
development of the market. This report likewise tracks and examines aggressive
improvements of the key players regarding market advancements, item portfolios,
and financials
Request Free Sample Copy - https://www.radiantinsights.com/research/peripheral-artery-disease-china-drug-forecast-and-market-analysis-to-2024/request-sample
In
the 2014 base year, the global PAD market was worth approximately $543.4m,
including both branded and generic drugs. By 2024, GlobalData expects that the
global PAD market will experience significant expansion, with a Compound Annual
Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The
dramatic increase in the value of the overall global PAD therapeutics market
will be partly attributable to the launch of several PAD drugs currently in
late-stage pipeline development, which GlobalData believes have extraordinary
potential. These include the novel antithrombotic pharmacological agents, Merck
& Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and
Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto
(rivaroxaban), which have the capacity to reform the antiplatelet and
anticoagulatory PAD treatment landscape.
In
2014, the PAD therapeutics market in China was worth approximately $93.7m.
Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of
approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on
warfarin's stake in the PAD market.
*This
is an on-demand report and will be delivered within 24 hrs. (excluding
weekends) of the purchase.
Scope
-
Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape.
-
Detailed information on the key drugs in China including product PADcription,
safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in China from 2014-2024.
-
Analysis of the impact of key events as well the drivers and restraints
affecting China PAD market.
Reasons to Buy
-
Understand and capitalize by identifying products that are most likely to
ensure a robust return
-
Stay ahead of the competition by understanding the changing competitive
landscape for PAD.
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth analysis of
drug performance
-
Obtain sales forecast for drugs from 2014-2024 in China
View Full Report at- https://www.radiantinsights.com/research/peripheral-artery-disease-china-drug-forecast-and-market-analysis-to-2024
This
report is a total investigation of ebb and flow inclines in the market,
business development drivers, and restrictions. It gives showcase projections
to the coming years. It incorporates investigation of late advancements in
innovation, Doorman's five power demonstrate examination and point by point
profiles of best industry players. The report additionally incorporates a
survey of miniaturized scale and large-scale factors fundamental for the
current market players and new participants alongside nitty gritty esteem chain
examination
About Us
Radiant
Insights is a market research and consulting company offering syndicated
research studies, customized reports, and consulting services. Our market
research studies are designed to facilitate strategic decision making, on the
basis of extensive and in-depth quantitative information, supported by
extensive analysis and industry insights. Using a patented and robust research
methodology, we publish exhaustive research reports covering a host of
industries such as Technology, Chemicals, Materials, and Energy. Radiant
Insights has a strong base of analysts, consultants and domain experts, with
global experience helping us deliver excellence in all research projects we
undertake
Contact Us
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
201
Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States
Tel:
1-415-349-0054
Toll
Free: 1-888-928-9744
No comments:
Post a Comment